Dihydromyricetin Attenuates Metabolic Syndrome And Improves Insulin Sensitivity By Upregulating Insulin Receptor Substrate-1 (Y612) Tyrosine Phosphorylation In db/db Mice.
Jidong HeJunpeng ZhangLijuan DongXuefeng DangLi WangLong ChengYunxiang HuangPublished in: Diabetes, metabolic syndrome and obesity : targets and therapy (2019)
In summary, we determined the antimetabolic syndrome effect of DHM in db/db obese mice. DHM upregulates the IRS-1 (Y612) tyrosine phosphorylation, improving insulin resistance. Therefore, DHM is a promising therapeutic candidate for the control of metabolic syndrome.